Shattuck Labs, Inc. (NASDAQ:STTK) Shares Sold by Jane Street Group LLC

Jane Street Group LLC cut its holdings in shares of Shattuck Labs, Inc. (NASDAQ:STTK) by 46.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 25,705 shares of the company’s stock after selling 22,703 shares during the period. Jane Street Group LLC owned about 0.05% of Shattuck Labs worth $90,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of STTK. FMR LLC grew its stake in Shattuck Labs by 0.4% during the 3rd quarter. FMR LLC now owns 7,159,090 shares of the company’s stock valued at $24,985,000 after purchasing an additional 26,460 shares in the last quarter. State Street Corp boosted its stake in shares of Shattuck Labs by 7.8% during the 3rd quarter. State Street Corp now owns 766,410 shares of the company’s stock valued at $2,675,000 after buying an additional 55,579 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Shattuck Labs by 83.1% during the second quarter. Renaissance Technologies LLC now owns 392,010 shares of the company’s stock worth $1,513,000 after buying an additional 177,910 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Shattuck Labs by 209.7% in the second quarter. Bank of New York Mellon Corp now owns 222,034 shares of the company’s stock worth $857,000 after buying an additional 150,340 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in Shattuck Labs by 44.1% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 178,228 shares of the company’s stock valued at $622,000 after acquiring an additional 54,505 shares in the last quarter. 58.74% of the stock is owned by hedge funds and other institutional investors.

Shattuck Labs Stock Down 5.9 %

Shares of NASDAQ:STTK opened at $1.12 on Wednesday. The company has a market cap of $53.47 million, a PE ratio of -0.73 and a beta of 1.71. Shattuck Labs, Inc. has a fifty-two week low of $0.94 and a fifty-two week high of $11.76. The firm has a 50-day simple moving average of $1.17 and a 200 day simple moving average of $2.39.

Wall Street Analyst Weigh In

Several brokerages have weighed in on STTK. Citigroup downgraded shares of Shattuck Labs from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $8.00 to $2.00 in a research report on Wednesday, October 2nd. Needham & Company LLC reissued a “hold” rating on shares of Shattuck Labs in a report on Thursday, November 14th. Evercore ISI upgraded Shattuck Labs to a “strong-buy” rating in a research note on Wednesday, October 2nd. Finally, HC Wainwright reiterated a “neutral” rating on shares of Shattuck Labs in a research report on Friday, November 15th. Four analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $8.67.

Insider Activity

In related news, Director Redmile Group, Llc purchased 133,371 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The shares were acquired at an average price of $1.25 per share, with a total value of $166,713.75. Following the acquisition, the director now owns 5,539,724 shares in the company, valued at approximately $6,924,655. This trade represents a 2.47 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 10.50% of the company’s stock.

Shattuck Labs Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.